Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 21

1545P - Phase II trial of endostar in combination with concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of esophagus

Date

21 Oct 2023

Session

Poster session 21

Topics

Radiation Oncology

Tumour Site

Oesophageal Cancer

Presenters

Yuexiao Qi

Citation

Annals of Oncology (2023) 34 (suppl_2): S852-S886. 10.1016/S0923-7534(23)01930-0

Authors

Y. Qi1, S. Wei2, L. Shao2

Author affiliations

  • 1 Radiation Oncology, The Tumor Hospital of Gansu Province, 730050 - Lanzhou/CN
  • 2 Radiation Oncology, Gansu Provincial Cancer Hospital, Lanzhou/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1545P

Background

To evaluate the efficacy and safety of Endostar combined with concurrent chemoradiotherapy (CCRT) in patients with locally advanced esophageal squamous cell carcinoma (ESCC).

Methods

From May 2017 to February 2021, 92 patients with unresectable thoracic ESCC, clinical staged as IB to IVB disease based on the 8th edition of the American Joint Committee on Cancer (stage IVB: Only metastasis to supraclavicular/celiac lymph nodes) and local recurrence, were enrolled and randomly allocated in Endostar plus concurrent chemoradiotherapy (CCRT)(intervention group; n=46) and concurrent chemoradiotherapy (CCRT) (control group; n=48). Five or six cycles of Endostar (7.5mg/m2/24h ×120h, 7 days/cycle) were delivered in intervention group. The primary endpoint was overall survival (OS). The secondary endpoints were progression-free survival (PFS), 1-year and 2-year overall survival rate and adverse events (AE).

Results

The median age was 63(interquartile range, 50-77) years in intervention group and 65(interquartile range, 52-79) years in control group. A total of 68 patients (74%) had stage III and IV disease. The intervention group had a significant higher complete response rate (ORR) than the control group (80% vs. 63.8%; P<0.05). The 1- and 2-year overall survival rates were 88.1% and 75.2% in intervention group, 87.4% and 62.3% in control group, respectively (P>0.05). The were no significant differences in the incidence of grade 3 or higher toxic effects between the intervention group and control group (P>0.05).

Conclusions

The median age was 63(interquartile range, 50-77) years in intervention group and 65(interquartile range, 52-79) years in control group. A total of 68 patients (74%) had stage III and IV disease. The intervention group had a significant higher complete response rate (ORR) than the control group (80% vs. 63.8%; P<0.05). The 1- and 2-year overall survival rates were 88.1% and 75.2% in intervention group, 87.4% and 62.3% in control group, respectively (P>0.05). The were no significant differences in the incidence of grade 3 or higher toxic effects between the intervention group and control group (P>0.05).

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.